etrasimod arginine · Pfizer · NDA 216956
Velsipity
Earliest generic entry, as listed
21 Jun 2036
Blocked by patent: US 10301262, US 10676435, US 11091435, US 11884626.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10301262 | substance, product | 21 Jun 2036 |
| US 10676435 | use U-3731 | 21 Jun 2036 |
| US 11091435 | substance, product | 21 Jun 2036 |
| US 11884626 | use U-3731 | 21 Jun 2036 |
| US 11007175 | use U-3730 | 6 Jan 2036 |
| US 12156866 | use U-4047 | 6 Jan 2036 |
| US 12377071 | use U-4255 | 6 Jan 2036 |
| US 8580841 | substance, product | 5 Mar 2030 |
| US 9126932 | use U-3732 | 22 Jul 2029 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 12 Oct 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 216956 · 001 · RLD | tablet, oral | EQ 2MG BASE | 21 Jun 2036 |